Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Gross

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
JCO Precision Oncology|March 7, 2024
TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline TestingStacy Loeb, Scott W Keith, Heather H Cheng, et al.
Contemporary Clinical Trials|June 16, 2022
Technology-enhanced AcceleRation of Germline Evaluation for Therapy (TARGET): A randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testingStacy Loeb, Heather H Cheng, Amy Leader, et al.
JCO Precision Oncology|September 19, 2025
Patient-Reported Outcomes From Males Regarding Germline Testing for Prostate Cancer: Results From the PROGRESS RegistryStacy Loeb, Scott W Keith, Laura Gross, et al.
BMC Public Health|September 17, 2024
Adaptation of the socioecological model to address disparities in engagement of Black men in prostate cancer genetic testingAmy E Leader, Timothy R Rebbeck, William K Oh, et al.
Nature Communications|September 21, 2017
Tumor-associated B-cells induce tumor heterogeneity and therapy resistanceRajasekharan Somasundaram, Gao Zhang, Mizuho Fukunaga-Kalabis, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
JCO Precision Oncology|March 7, 2024
TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline TestingStacy Loeb, Scott W Keith, Heather H Cheng, et al.
Contemporary Clinical Trials|June 16, 2022
Technology-enhanced AcceleRation of Germline Evaluation for Therapy (TARGET): A randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testingStacy Loeb, Heather H Cheng, Amy Leader, et al.
JCO Precision Oncology|September 19, 2025
Patient-Reported Outcomes From Males Regarding Germline Testing for Prostate Cancer: Results From the PROGRESS RegistryStacy Loeb, Scott W Keith, Laura Gross, et al.
BMC Public Health|September 17, 2024
Adaptation of the socioecological model to address disparities in engagement of Black men in prostate cancer genetic testingAmy E Leader, Timothy R Rebbeck, William K Oh, et al.
Nature Communications|September 21, 2017
Tumor-associated B-cells induce tumor heterogeneity and therapy resistanceRajasekharan Somasundaram, Gao Zhang, Mizuho Fukunaga-Kalabis, et al.
Pageof 3